261 related articles for article (PubMed ID: 18483104)
21. [Paradoxical effect of radioiodine therapy in functional thyroid autonomy and mild immunothyropathy].
Dunkelmann S; Rudolph F; Prillwitz A; Groth P; Schümichen C
Nuklearmedizin; 1998 Jan; 37(1):23-9. PubMed ID: 9467166
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.
Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK
Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116
[TBL] [Abstract][Full Text] [Related]
23. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
[TBL] [Abstract][Full Text] [Related]
24. Age influences the severity of Graves' ophthalmopathy.
Lin MC; Hsu FM; Bee YS; Ger LP
Kaohsiung J Med Sci; 2008 Jun; 24(6):283-8. PubMed ID: 18635413
[TBL] [Abstract][Full Text] [Related]
25. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine.
Abraham-Nordling M; Wallin G; Träisk F; Berg G; Calissendorff J; Hallengren B; Hedner P; Lantz M; Nyström E; Asman P; Lundell G; Törring O;
Eur J Endocrinol; 2010 Oct; 163(4):651-7. PubMed ID: 20660002
[TBL] [Abstract][Full Text] [Related]
26. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism.
Manso PG; Furlanetto RP; Wolosker AM; Paiva ER; de Abreu MT; Maciel RM
Thyroid; 1998 Jan; 8(1):49-52. PubMed ID: 9492153
[TBL] [Abstract][Full Text] [Related]
27. Graves' ophthalmopathy in patients treated with radioiodine 131-I.
Bałdys-Waligórska A; Gołkowski F; Kusnierz-Cabala B; Buziak-Bereza M; Hubalewska-Dydejczyk A
Endokrynol Pol; 2011; 62(3):214-9. PubMed ID: 21717402
[TBL] [Abstract][Full Text] [Related]
28. Pediatric aspects in Graves' orbitopathy.
Gogakos AI; Boboridis K; Krassas GE
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():234-44. PubMed ID: 20467370
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of radioiodine 131I treatment in Graves' disease patients with mild orbitopathy].
Bałdys-Waligórska A; Stefańska A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
Przegl Lek; 2009; 66(4):166-9. PubMed ID: 19708504
[TBL] [Abstract][Full Text] [Related]
30. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
31. Postural variation of exophthalmometry in Graves' ophthalmopathy.
Asad R; Tewari HK; Ahuja MM; Mithal A
Indian J Ophthalmol; 1990; 38(4):166-8. PubMed ID: 2086467
[TBL] [Abstract][Full Text] [Related]
32. [Radioiodine therapy for Graves' disease: problems and new developments].
Reiners C
Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():55-62. PubMed ID: 15255314
[TBL] [Abstract][Full Text] [Related]
33. Health effects of therapeutic use of 131I in hyperthyroidism.
Pauwels EK; Smit JW; Slats A; Bourguignon M; Overbeek F
Q J Nucl Med; 2000 Dec; 44(4):333-9. PubMed ID: 11302261
[TBL] [Abstract][Full Text] [Related]
34. [Corticosteroids and radiotherapy in the treatment of Graves' ophthalmopathy].
Nasr E; Khater S; Nehme-Nasr D; Azoury F; Jambart S
J Med Liban; 2010; 58(2):86-90. PubMed ID: 20549894
[TBL] [Abstract][Full Text] [Related]
35. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy.
Martins JR; Furlanetto RP; Oliveira LM; Mendes A; Passerotti CC; Chiamolera MI; Rocha AJ; Manso PG; Nader HB; Dietrich CP; Maciel RM
Clin Endocrinol (Oxf); 2004 Jun; 60(6):726-33. PubMed ID: 15163337
[TBL] [Abstract][Full Text] [Related]
36. A possible method using baseline hormonal levels to prescribe the appropriate oral therapeutic radioiodine dosage for Graves' disease.
Nakajo M; Tsuchimochi S; Jinguji M; Tanabe H; Umanodan T; Nakabeppu Y
Ann Nucl Med; 2007 Oct; 21(8):471-6. PubMed ID: 17952556
[TBL] [Abstract][Full Text] [Related]
37. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
[TBL] [Abstract][Full Text] [Related]
38. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
39. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of Graves' disease: results of a prospective study.
Eschmann SM; Thelen MH; Dittmann H; Bares R
Exp Clin Endocrinol Diabetes; 2006 May; 114(5):222-6. PubMed ID: 16804795
[TBL] [Abstract][Full Text] [Related]
40. Treating the thyroid in the presence of Graves' ophthalmopathy.
Hegedüs L; Bonnema SJ; Smith TJ; Brix TH
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):313-24. PubMed ID: 22632368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
